clinical trial · NCT05880706
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.·phase2·active not recruiting·n = 198
Non-small Cell Lung CancerBL-B01D1Osimertinib Mesylate Tablets
brief summary
A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with locally advanced or metastatic non-small cell lung cancer.
started
Jul 19, 2023
primary completion
Jul 1, 2027
completion
Jul 1, 2027
last updated
Sep 19, 2025
official title
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol